MX2023010831A - Composiciones y metodos para tratar enfermedades neurologicas. - Google Patents

Composiciones y metodos para tratar enfermedades neurologicas.

Info

Publication number
MX2023010831A
MX2023010831A MX2023010831A MX2023010831A MX2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A
Authority
MX
Mexico
Prior art keywords
methods
compositions
neurologic diseases
treating neurologic
treating
Prior art date
Application number
MX2023010831A
Other languages
English (en)
Spanish (es)
Inventor
Gilbert M Rishton
Susan M Catalano
Gary C Look
Anthony Caggiano
Mary Hamby
Nicholas Izzo
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of MX2023010831A publication Critical patent/MX2023010831A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023010831A 2021-03-19 2022-03-17 Composiciones y metodos para tratar enfermedades neurologicas. MX2023010831A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163163546P 2021-03-19 2021-03-19
PCT/US2022/020687 WO2022197885A1 (en) 2021-03-19 2022-03-17 Compositions and methods for treating neurologic diseases

Publications (1)

Publication Number Publication Date
MX2023010831A true MX2023010831A (es) 2023-09-27

Family

ID=83320987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010831A MX2023010831A (es) 2021-03-19 2022-03-17 Composiciones y metodos para tratar enfermedades neurologicas.

Country Status (10)

Country Link
US (2) US20240165077A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308565A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024510249A (cg-RX-API-DMAC7.html)
KR (1) KR20230159546A (cg-RX-API-DMAC7.html)
CN (1) CN117355525A (cg-RX-API-DMAC7.html)
AU (1) AU2022239497A1 (cg-RX-API-DMAC7.html)
CA (1) CA3212092A1 (cg-RX-API-DMAC7.html)
IL (1) IL306063A (cg-RX-API-DMAC7.html)
MX (1) MX2023010831A (cg-RX-API-DMAC7.html)
WO (1) WO2022197885A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用
WO2026064542A1 (en) * 2024-09-18 2026-03-26 Cognition Therapeutics, Inc. 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts in solid forms
WO2026119142A1 (zh) * 2024-12-03 2026-06-11 浙江径科医药有限公司 一种氘代异吲哚啉化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
WO2013029057A2 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
WO2015116923A1 (en) * 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
US20200000822A1 (en) * 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
US20200338045A1 (en) * 2017-11-01 2020-10-29 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
JP2022537581A (ja) * 2019-06-21 2022-08-26 クラリス コーポレーション Ppm1阻害剤およびその使用方法
CN110283082A (zh) * 2019-07-15 2019-09-27 泰州职业技术学院 一种3-苯基丙胺的制备方法

Also Published As

Publication number Publication date
CN117355525A (zh) 2024-01-05
AU2022239497A1 (en) 2023-09-21
EP4308565A4 (en) 2025-01-01
WO2022197885A1 (en) 2022-09-22
KR20230159546A (ko) 2023-11-21
US20240165077A1 (en) 2024-05-23
US20260166006A1 (en) 2026-06-18
IL306063A (en) 2023-11-01
CA3212092A1 (en) 2022-09-22
EP4308565A1 (en) 2024-01-24
JP2024510249A (ja) 2024-03-06

Similar Documents

Publication Publication Date Title
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
MY208749A (en) Biligand drug conjugates and uses thereof
EP4548918A3 (en) Tricyclic compounds as inhibitors of kras
ZA202109010B (en) Compounds and methods for the treatment of covid-19
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MX2020012180A (es) Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina.
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
TW200806299A (en) Treatment of pain
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
MA55027B1 (fr) Formulations plaisante au goût
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
WO2020257631A3 (en) Ppm1a inhibitors and methods of using same
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
WO2022246251A3 (en) Compounds for modulating unc13a expression
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
CA2864606C (en) Methods of treating and preventing diseases and disorders of the central nervous system
TW200639159A (en) Treatment of pain
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
KR102467285B9 (ko) 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물
WO2024141660A3 (en) Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases
WO2023107630A3 (en) Amino alcohol compounds and uses thereof